Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura

Next Previous
Trial Profile

A Multicenter, Randomized, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ubrogepant (Primary)
  • Indications Migraine; Migraine with aura; Migraine without aura
  • Focus Adverse reactions; Registrational
  • Sponsors Allergan

    • Most Recent Events

    • 17 Aug 2022 Results (n=808) of a post-hoc analysis assessing influence of baseline pain intensity on treatment outcomes published in the Neurology
    • 12 Jun 2022 Results of post-hoc analysis assessing the efficacy of ubrogepant 50 or 100 mg within participants who treated migraine attacks with mild and moderate/severe pain during a 52- week treatment period presented at the 64th Annual Scientific Meeting of the American Headache Society
    • 12 Jun 2022 Results assessing participant- reported out-comes of normal function and satisfaction 2 hours post- treatment with long-term intermittent use of ubrogepant as an acute treatment of migraine attacks, presented at the 64th Annual Scientific Meeting of the American Headache Society.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top